| Cat. No. |
Product Name |
CAS No. |
Information |
| GY03856 |
CB-03-01
|
19608-29-8 |
Cortexolone 17 alpha-propionate (CB-03-01, Clascoterone) is a topical and peripherally selective androgen antagonist, displays a strong local antiandrogenic activity in hamster's flank organ test, does not exhibit antiandrogenic activity after subcutaneous injection in vivo. |
| GY03855 |
RU58841
|
154992-24-2 |
A nonsteroidal, specific androgen receptor inhibitor; be useful for the topical treatment of androgen-dependent skin disorders such as acne, androgenetic alopecia and hirsutism. |
| GY10096 |
KCI807
|
6665-68-5 |
KCI807 (KCI-807) is a lead molecule that selectively disrupts ELK1-dependent promoter activation by wild-type and variant Ars (IC50=0.53 uM) without interfering with ELK1 activation by ERK; binds to AR (Kd=69.2 nM), blocking ELK1 binding, and selectively blocks recruitment of AR to chromatin by ELK1; primarily affects a subset of AR target growth genes selectively suppressing AR-dependent growth of PC cell lines with a better inhibitory profile than Enzalutamide; also inhibits in vivo growth of castration/enzalutamide-resistant cell line-derived and patient-derived tumor xenografts. |
| GY10282 |
IMTPPE
|
|
IMTPPE (SID 3712502) is a novel small molecule capable of inhibiting androgen receptor (AR) transcriptional activity (IC50=1 uM) and protein level in C4-2 prostate cancer cells; IMTPPE inhibited proliferation of AR-positive, but not AR-negative, prostate cancer cells in culture. IMTPPE inhibited the transcriptional activity of a mutant AR lacking the ligand-binding domain (LBD); IMTPPE inhibited the growth of 22Rv1 xenograft tumor, a model for enzalutamide-resistant prostate cancer. |
| GY10072 |
UT-34
|
2168525-92-4 |
UT-34 is a selective androgen receptor degrader (SARD) ligand.Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer. |
| GY02293 |
N-desmethyl Enzalutamide
|
1242137-16-1 |
Amajor metabolite of Enzalutamide (MDV3100) which is an androgen-receptor (AR) antagonist for treatment of prostate cancer. |
| GY04046 |
LGD4033
|
1165910-22-4 |
A novel nonsteroidal, oral selective androgen receptor modulator (SARM), binds androgen receptor with high affinity (Ki=1 nM) and selectivity; has favorable pharmacokinetic profile, and increases lean body mass even during this short period without change in prostate-specific antigen. |
| GY03800 |
LGD-3033
|
917891-35-1 |
LGD-3303 is an orally available, brain-penetrant nonsteroidal selective androgen receptor modulator (SARM) that that shows little or no cross-reactivity with related nuclear receptors; has potent activity on levator ani muscle but is a partial agonist on the preputial gland and ventral prostate in a castrated rat model of androgen deficiency; enhances male-directed sexual preference, proceptive behavior, and lordosis behavior in sexually experienced, but not sexually naive, female rats. |
| GY01611 |
ODM-201
|
1297538-32-9 |
Darolutamide (ODM-201;BAY-1841788) is a potent wt/mutant androgen receptor (AR) inhibitor with Ki of 11 nM; inhibits wtAR/AR(F876L) with IC50 of 65/66 nM respectively, weak inhibition on AR(W741L) and AR(T877A); inhibits the nuclear translocation of AR and more efficaciously than enzalutamide or ARN-509 in VCaP cell line proliferation assay; reduces the growth of AR-overexpressing VCaP prostate cancer cells both in vitro and in a castration-resistant VCaP xenograft model. |
| GY01602 |
Andarine
|
401900-40-1 |
Andarine (S-4;GTx007) is a non-steroidal selective androgen receptor modulator (SARM) with Ki of 4 nM, efficaciously stimulated AR-mediated reporter gene expression; demonstrates in vivo androgenic and anabolic activity, stimulates the anabolic organs more than the androgenic organs; improves muscle strength and body composition and prevents bone loss in orchidectomized rats. |
$ USD
Select Your Country or Region
